Sign inCreate account

Report workspace tools

NCT07061145RECRUITINGanonymous

A Potential Relationship Between Treatment With Tyrosine Kinase Inhibitors and Erectile Dysfunction in Male Patients With Chronic Myeloid Leukemia

Sponsor

Source record

Azienda USL Reggio Emilia - IRCCS

Phase

Source record

registry-stage

Modality

AI-normalized

small molecule

Target

AI-normalized

Tirosin Kinase Inhibitors

Indication / condition

AI-normalized

Chronic Myelocytic Leukemia

Intervention

Source record

Tirosin Kinase Inhibitors

Source & freshness

Source record

NCT ID

NCT07061145

Original source

ClinicalTrials.gov

Source last updated

Aug 06, 2025

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT07061145

Title

A Potential Relationship Between Treatment With Tyrosine Kinase Inhibitors and Erectile Dysfunction in Male Patients With Chronic Myeloid Leukemia

Sponsor

Azienda USL Reggio Emilia - IRCCS

Status

RECRUITING

Phase

registry-stage

Condition raw

Chronic Myelocytic Leukemia

Condition normalized

Chronic Myelocytic Leukemia

Modality raw

chronic kidney disease obesity

Modality normalized

small molecule

Target raw

Tirosin Kinase Inhibitors

Target normalized

Tirosin Kinase Inhibitors

Interventions

Tirosin Kinase Inhibitors

Public preview

Source record

A Potential Relationship Between Treatment With Tyrosine Kinase Inhibitors and Erectile Dysfunction in Male Patients With Chronic Myeloid Leukemia is a registry-stage clinical asset sponsored by Azienda USL Reggio Emilia - IRCCS in Chronic Myelocytic Leukemia, Erectile Dysfunctions, CVD - Cardiovascular Disease, Tyrosine Kinase Inhibitor. SEO and diligence focus: Tirosin Kinase Inhibitors, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Potential Relationship Between Treatment With Tyrosine Kinase Inhibitors and Erectile Dysfunction in Male Patients With Chronic Myeloid Leukemia

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT07061145

Status

RECRUITING

Phase

registry-stage

Sponsor

Azienda USL Reggio Emilia - IRCCS

Executive brief

Investment-Ready Snapshot

A Potential Relationship Between Treatment With Tyrosine Kinase Inhibitors and Erectile Dysfunction in Male Patients With Chronic Myeloid Leukemia is a registry-stage clinical asset sponsored by Azienda USL Reggio Emilia - IRCCS in Chronic Myelocytic Leukemia, Erectile Dysfunctions, CVD - Cardiovascular Disease, Tyrosine Kinase Inhibitor. SEO and diligence focus: Tirosin Kinase Inhibitors, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedAug 06, 2025
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT07061145

Indication

Chronic Myelocytic Leukemia

Modality

small molecule

Target

Tirosin Kinase Inhibitors

Intervention

Tirosin Kinase Inhibitors

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.